Dec 15 (Reuters) - CSL Ltd (CSL) :
- GARADACIMAB RECEIVES FDA AND EMA FILING ACCEPTANCE
- ORPHAN-DRUG DESIGNATION FOR GARADACIMAB AS A THERAPY FOR HEREDITARY ANGIOEDEMA GRANTED BY BOTH FDA AND EMA
(([email protected];))
Dec 15 (Reuters) - CSL Ltd (CSL) : GARADACIMAB RECEIVES FDA AND...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.60 |
Change
4.560(1.51%) |
Mkt cap ! $148.1B | |||
| Open | High | Low | Value | Volume |
| $303.41 | $306.68 | $303.01 | $215.1M | 707.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | $306.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.68 | 284 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |